1998
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models
Herbst R, Takeuchi H, Teicher B. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemotherapy And Pharmacology 1998, 41: 497-504. PMID: 9554595, DOI: 10.1007/s002800050773.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow CellsCarboplatinCarcinoma, Lewis LungCell SurvivalColony-Forming Units AssayCyclohexanesDrug SynergismDrug Therapy, CombinationFemaleMaleMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CMice, Inbred C57BLMinocyclineNeovascularization, PathologicO-(Chloroacetylcarbamoyl)fumagillolPaclitaxelSesquiterpenesConceptsTNP-470/minocyclineEMT-6 mammary carcinomaBone marrow CFU-GMLewis lung carcinomaMarrow CFU-GMEMT-6 tumor cellsLung carcinomaMammary carcinomaCFU-GMNormal tissuesTumor cellsHigh-dose paclitaxelCell lung cancerCombination of paclitaxelToxicity of carboplatinEfficacy of chemotherapyTumor growth delayBreast carcinoma modelCytotoxicity of carboplatinEarly time pointsAgent regimenAntiangiogenic regimenCarboplatin administrationLung metastasesCell lungAcute in vivo resistance in high-dose therapy.
Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E. Acute in vivo resistance in high-dose therapy. Clinical Cancer Research 1998, 4: 483-91. PMID: 9516940.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCyclophosphamideDisease Models, AnimalDose-Response Relationship, DrugDrug Resistance, MultipleDrug Resistance, NeoplasmFemaleMammary Neoplasms, ExperimentalMelphalanMiceMice, Inbred BALB CNeoplasm TransplantationPaclitaxelThiotepaConceptsTumor growth delayAdditive tumor growth delayHigh-dose cyclophosphamideHigh-dose melphalanGrowth delaySecond highest doseHigh doseSequential high-dose chemotherapyTumor cell survival assayEMT-6 mammary carcinomaTumor growth delay studiesBone marrow colony-forming unitsHigh-dose therapyMarrow colony-forming unitsHigh-dose chemotherapyBone marrow CFU-GMHigh-dose treatmentGrowth delay studiesTumor-bearing miceMarrow CFU-GMSolid tumor modelsCell survival assayCombination regimensMammary carcinomaCyclophosphamide
1997
PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
Teicher B, Ara G, Herbst R, Takeuchi H, Keyes S, Northey D. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy. In Vivo 1997, 11: 301-11. PMID: 9292296.Peer-Reviewed Original ResearchConceptsPEG-hemoglobinTumor growth delayMammary carcinomaTumor cell killingSolid tumorsTumor oxygenationGrowth delayDose of chemotherapyEMT-6 murine mammary carcinomaBone marrow CFU-GMEfficacy of chemotherapyEMT-6 tumorsMurine mammary carcinomaTumor-bearing miceCFU-GM survivalMarrow CFU-GMCell killingOxygen delivery agentEMT-6 tumor-bearing miceChemotherapy administrationLung metastasesMultiple dosesSingle dosesChemotherapyCFU-GMTransforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. In Vivo 1997, 11: 463-72. PMID: 9509296.Peer-Reviewed Original ResearchConceptsBone marrow CFU-GMMarrow CFU-GMAdministration of decorinParent tumorCFU-GMTumor linesBALB/c miceEffects of secretionsC micePlasma levelsVivo resistanceMonolayer culturesSolid tumorsTherapeutic resistanceTumorsTumor modelDrug resistanceDrug sensitivityDosage rangeThiotepaMelphalanCell linesCisplatinAdministrationAnimals